Neurosense Therapeutics Ltd. (NRSN) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NeuroSense Therapeutics Ltd. has successfully completed the 18-month dosing phase of its PARADIGM Phase 2b ALS clinical trial, with top-line clinical results expected in early December 2024. Investors and market watchers will be keenly anticipating these results, which could significantly impact the company’s future prospects and stock performance.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.